DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Intermittent Claudication - Pipeline Review, H2 2016" report to their offering.
'Intermittent Claudication - Pipeline Review, H2 2016'; Intermittent Claudication pipeline therapeutics constitutes close to 5 molecules. which approximately 5 molecules are developed by Companies.
Intermittent Claudication Intermittent claudication is caused by narrowing or blockage in the main artery that takes blood to leg. Symptoms include burning or tingling sensation, decreased or absent pulse in the lower limb, pale or bluish skin, poor hair growth on the legs and sores or wounds on the lower limb that heal slowly, poorly. Risk factors include smoking, high cholesterol, high blood pressure, obesity, diabetes, age and family history.
The report 'Intermittent Claudication - Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Intermittent Claudication, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews of key players involved in therapeutic development for Intermittent Claudication and features dormant and discontinued projects. Currently, The molecules developed by Companies in Phase II and Discovery stages are 4 and 1 respectively.
Key Topics Covered:
- Intermittent Claudication Overview
- Therapeutics Development
- Pipeline Products for Intermittent Claudication - Overview
- Pipeline Products for Intermittent Claudication - Comparative Analysis
- Intermittent Claudication - Therapeutics under Development by Companies
- Intermittent Claudication - Therapeutics under Investigation by Universities/Institutes
- Intermittent Claudication Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Intermittent Claudication - Products under Development by Companies
- Intermittent Claudication - Products under Investigation by Universities/Institutes
- Intermittent Claudication - Companies Involved in Therapeutics Development
- ID Pharma Co., Ltd.
- Kowa Company, Ltd.
- Nuo Therapeutics, Inc.
- Pluristem Therapeutics Inc.
For more information about this report visit http://www.researchandmarkets.com/research/xvxh3r/intermittent